← Leaderboards
Herbert Pang
Duke University
$421,842
Attributed
$1,141,560
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $260.8K · FY2013–22$500K$375K$250K$125K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
FDA$768,098 · 1
NIH$373,462 · 1
By mechanism
U01$768,098 · 1
R21$373,462 · 1
Top collaborators
- Michael R Kosorok3 shared
- Jiawen Zhu3 shared
- Xiaofei Wang2 shared
- Grazyna Lieberman1 shared
Most similar at Duke University
Same institution · by research overlap
- Cathleen S Colon-Emeric$11,044,351
- Harvey Jay Cohen$25,592,956
- Joellen M. Schildkraut$37,778,185
- Ruth A Anderson$7,356,329
- Matthew J Ellis$25,349,408
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseBenefits And RisksCancer EtiologyCancer PatientCellsCessation Of LifeCharacteristicsChemoradiationChemotherapyClinical PracticeClinical ResearchClinical TrialsClinical Trials Cooperative GroupCommitCommunitiesComparative EfficacyConflict (Psychology)Data AggregationDatabasesData SetDesignDiagnosisEffectivenessAdverse Event
Grant awards (5)
Applying novel statistical approaches to develop a decision framework for hybrid randomized controlled trial designs which combine internal control arms with patients' data from real-world data source$260,757
U01 · FY2022 · FD · contact PI
Applying novel statistical approaches to develop a decision framework for hybrid randomized controlled trial designs which combine internal control arms with patients' data from real-world data source$256,284
U01 · FY2021 · FD · contact PI
Applying novel statistical approaches to develop a decision framework for hybrid randomized controlled trial designs which combine internal control arms with patients' data from real-world data source$251,057
U01 · FY2020 · FD
Translational meta-analysis for elderly lung cancer patients$166,321
R21 · FY2014 · AG
Translational meta-analysis for elderly lung cancer patients$207,141
R21 · FY2013 · AG